Abstract：
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in social communication and interaction, as well as restricted and repetitive patterns of behavior. Despite extensive research, effective pharmacological interventions for ASD remain limited. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has potential therapeutic effects on several neurological and psychiatric disorders. CBD interacts with the endocannabinoid system, a complex cell-signaling system that plays a crucial role in regulating various physiological processes, maintaining homeostasis, participating in social and behavioral processing, and neuronal development and maturation with great relevance to ASD. Furthermore, preliminary findings from clinical trials indicate that CBD may have a modulatory effect on specific ASD symptoms and comorbidities in humans. Interestingly, emerging evidence suggests that CBD may influence the gut microbiota, with implications for the bidirectional communication between the gut and the central nervous system. CBD is a safe drug with low induction of side effects. As it has a multi-target pharmacological profile, it becomes a candidate compound for treating the central symptoms and comorbidities of ASD.
摘要：
自闭症谱系障碍（ASD）是一种神经发育状况，其特征是社会交流和互动的持续缺陷，以及受限和重复的行为模式。尽管进行了广泛的研究,ASD的有效药物干预措施仍然有限。大麻二酚（CBD），大麻属植物的一种非拟态化合物，对几种神经和精神疾病有潜在的治疗作用。CBD与内源性大麻素系统相互作用，一个复杂的细胞信号系统，在调节各种生理过程中起着至关重要的作用，保持体内平衡，参与社会和行为处理，和神经元的发育和成熟与ASD密切相关。此外，临床试验的初步结果表明，CBD可能对人类特定的ASD症状和合并症有调节作用。有趣的是,新的证据表明，CBD可能会影响肠道微生物群，对肠道和中枢神经系统之间的双向通信有影响。CBD是一种安全的药物，副作用低。由于它具有多靶标药理学特征，它成为治疗ASD的中枢症状和合并症的候选化合物。
